dclre1c Antibody

What is DCLRE1C/Artemis and why is it important in immunological research?

DCLRE1C (Artemis) is a nuclear protein belonging to the metallo-β-lactamase superfamily that plays essential roles in adaptive immunity and genomic stability. It functions as a component of the non-homologous end-joining (NHEJ) pathway and is required for the assembly of B cell antibody genes and T cell receptor genes from individual V, D, and J segments . During V(D)J recombination, Artemis forms a complex with DNA-dependent protein kinase (DNA-PK) and cuts DNA with hairpin structure, enabling proper lymphocyte development . Deficiency in Artemis results in blocking of V(D)J recombination and failure to produce mature B and T cells, leading to severe combined immune deficiency (SCID) . Additionally, Artemis is involved in the termini processing step of double-strand break repair, making it relevant for studies on DNA damage response mechanisms .

What are the optimal applications for DCLRE1C antibodies in laboratory settings?

DCLRE1C antibodies can be effectively utilized in multiple laboratory applications, with specific optimization parameters for each technique:

For accurate results, researchers should validate antibody specificity for their particular experimental conditions, as reactivity can vary across species including human, mouse, rat, and others as indicated in product specifications .

How should researchers select between different DCLRE1C antibody epitope targets?

When selecting a DCLRE1C antibody, researchers should consider the specific epitope target based on their experimental design and research questions. Multiple antibodies target different regions of the DCLRE1C protein:

• N-terminal targeted antibodies (amino acids 21-50) are useful for detecting the full-length protein and are often generated from rabbits immunized with KLH-conjugated synthetic peptides .

• C-terminal targeted antibodies can detect endogenous levels of total DCLRE1C and are purified by peptide affinity chromatography .

• Internal region antibodies may provide alternate detection options.

The choice should be informed by protein structure considerations, potential post-translational modifications, and whether specific isoforms need to be detected. Functional studies have demonstrated that the full-length isoform a (692 amino acids) exhibits significantly higher activity than shorter isoforms b and c , so antibodies targeting conserved regions across isoforms may provide more consistent results for general detection purposes.

How can researchers optimize DCLRE1C antibody-based immunostaining protocols?

Optimizing immunostaining with DCLRE1C antibodies requires careful attention to several critical parameters:

• Fixation method: For cellular localization studies, using 4% paraformaldehyde is recommended as it preserves nuclear structure where DCLRE1C primarily localizes.

• Antigen retrieval: For FFPE tissue sections, heat-induced epitope retrieval using citrate buffer (pH 6.0) typically provides optimal results.

• Blocking parameters: Use 5-10% serum from the same species as the secondary antibody for 1 hour at room temperature to minimize background.

• Primary antibody incubation: For most applications, dilutions between 1:50-1:200 with overnight incubation at 4°C yield the most specific signal .

• Detection systems: For low abundance targets like DCLRE1C, amplification systems such as tyramide signal amplification may enhance sensitivity.

• Counterstaining: Nuclear counterstains like DAPI are particularly useful since DCLRE1C is a nuclear protein.

When analyzing results, researchers should be mindful that DCLRE1C expression patterns may vary significantly between different cell types, with highest expression typically observed in lymphoid tissues where V(D)J recombination actively occurs .

What are the critical validation steps for ensuring DCLRE1C antibody specificity?

Validating DCLRE1C antibody specificity is essential for generating reliable research data. A comprehensive validation approach should include:

• Positive and negative controls: Use tissues/cells known to express DCLRE1C (lymphoid tissues) and those with minimal expression or knockout models.

• Multiple detection methods: Confirm specificity using at least two independent techniques (e.g., Western blot plus immunohistochemistry).

• Peptide competition assays: Pre-incubation of antibody with the immunizing peptide should eliminate specific signal.

• Genetic models: Testing in DCLRE1C-deficient models (Dclre1c^-/-) as demonstrated in functional studies provides definitive validation .

• Molecular weight verification: Confirm that detected bands match the expected molecular weight of DCLRE1C isoforms (approximately 78 kDa for the full-length isoform a).

• Cross-reactivity assessment: If working across species, verify specificity for each target organism separately, as cross-reactivity may not be uniform despite predicted reactivity .

These validation steps should be documented systematically and included in research publications to enhance reproducibility and reliability of findings.

How can DCLRE1C antibodies be utilized to study V(D)J recombination defects?

DCLRE1C antibodies can be powerful tools for investigating V(D)J recombination defects in both research and clinical contexts:

• Immunophenotyping: Researchers can use DCLRE1C antibodies in flow cytometry or immunohistochemistry to characterize DCLRE1C expression levels in patient-derived lymphocytes or cell lines, potentially identifying cases with protein expression but functional defects.

• Co-immunoprecipitation studies: DCLRE1C antibodies can help identify interaction partners in the V(D)J recombination machinery, particularly the critical interaction with DNA-PK which is essential for hairpin opening activity .

• Chromatin immunoprecipitation (ChIP): Using DCLRE1C antibodies for ChIP experiments can reveal genomic binding sites during active V(D)J recombination, providing insights into the spatial and temporal dynamics of recombination events.

• Functional complementation assays: Similar to the approach described in search result , researchers can use DCLRE1C antibodies to confirm expression of introduced wild-type or mutant DCLRE1C constructs in Dclre1c^-/- cells when performing functional rescue experiments.

• Post-translational modification analysis: Phospho-specific DCLRE1C antibodies (such as those detecting pSer516) can reveal regulatory mechanisms controlling Artemis activity in response to DNA damage or during V(D)J recombination .

These approaches have proven valuable in characterizing the spectrum of DCLRE1C mutations associated with different clinical phenotypes, from severe SCID to milder "leaky SCID" presentations .

What methodologies are recommended for studying DCLRE1C in DNA damage response pathways?

For investigating DCLRE1C's role in DNA damage response pathways, researchers should consider these methodological approaches:

• γH2AX resolution assays: As described in the literature, DCLRE1C function can be assessed by monitoring the resolution of γH2AX foci after ionizing radiation. This approach allows quantification of DNA repair efficacy using flow cytometry or immunofluorescence with DCLRE1C antibodies to correlate protein expression with repair capacity .

• Live-cell imaging: Combining DCLRE1C antibodies (or fluorescently tagged DCLRE1C constructs) with DNA damage markers enables temporal analysis of DCLRE1C recruitment to damage sites.

• Laser microirradiation: This technique creates localized DNA damage, allowing researchers to study DCLRE1C recruitment kinetics to damage sites using fluorescently labeled antibodies.

• Comet assay integration: Researchers can correlate DCLRE1C expression levels (determined by antibody-based techniques) with DNA repair capacity measured by comet assay following exposure to DNA damaging agents.

• Radiosensitivity analysis: Cells with varying DCLRE1C expression levels (quantified via antibody-based assays) can be assessed for survival following radiation exposure to establish dose-response relationships.

These methodologies have revealed that Artemis-deficient cells display increased sensitivity to double-strand breaks induced by ionizing radiation or chemical agents such as bleomycin and neocarzinostatin , highlighting DCLRE1C's importance beyond V(D)J recombination.

How can researchers effectively use DCLRE1C antibodies in multiplex immunoassays?

Integrating DCLRE1C antibodies into multiplex immunoassays requires careful planning:

• Antibody panel design: When designing multiplex panels, select DCLRE1C antibodies that are compatible with other target antibodies in terms of species origin and isotype to avoid cross-reactivity. Polyclonal DCLRE1C antibodies from rabbit sources are commonly available and can be paired with monoclonal antibodies from different species .

• Fluorophore selection: For fluorescence-based multiplex assays, assign fluorophores to DCLRE1C antibodies based on expected expression levels—use brighter fluorophores for potentially low-abundance expression.

• Optimization strategies:

  • Titrate each antibody individually before combining

  • Perform controls for spectral overlap compensation

  • Test for antibody cross-reactivity or blocking effects

• Sequential staining: For complex multiplex panels, consider sequential staining approaches where DCLRE1C antibody is applied in a separate step from potentially cross-reactive antibodies.

• Data analysis: Use dimensionality reduction techniques (tSNE, UMAP) when analyzing multiplex data to identify cell populations with distinct DCLRE1C expression patterns in relation to other markers.

Through these approaches, researchers can effectively examine DCLRE1C in the context of other DNA repair proteins or immune cell markers, providing a systems-level view of its function in various cellular processes.

What are common technical challenges with DCLRE1C antibodies and how can they be resolved?

Researchers may encounter several challenges when working with DCLRE1C antibodies:

For improved results, researchers should note that DCLRE1C antibodies typically require careful optimization of application protocols. For example, Western blotting applications may benefit from extended transfer times due to the relatively high molecular weight of DCLRE1C, while immunohistochemistry applications often require heat-mediated antigen retrieval for optimal epitope accessibility .

How should researchers interpret variable DCLRE1C antibody staining patterns in different cell types?

Variation in DCLRE1C staining patterns across different cell types requires careful interpretation:

• Expression level differences: DCLRE1C expression is typically highest in developing lymphocytes where V(D)J recombination occurs, but may be detected at lower levels in other cell types involved in DNA repair processes. Quantitative comparisons should account for these baseline differences .

• Subcellular localization: While predominantly nuclear, DCLRE1C may show dynamic localization changes in response to DNA damage or cell cycle changes. These patterns should be interpreted in the context of the specific cellular state.

• Isoform differences: The full-length 692 amino acid isoform (variant a) shows significantly higher functional activity than shorter isoforms . Antibodies targeting different regions may preferentially detect specific isoforms, resulting in apparently discordant staining patterns.

• Post-translational modifications: Modified forms of DCLRE1C (such as phosphorylated variants) may show altered epitope accessibility or localization patterns. Phospho-specific antibodies targeting sites like Ser516 may reveal regulatory mechanisms not apparent with antibodies against total DCLRE1C .

• Disease-related alterations: In cells from patients with DCLRE1C mutations, antibody staining patterns may reveal important information about protein expression, stability, or localization that correlates with disease severity .

Researchers should systematically document these variations and correlate them with functional assays when possible to enhance biological interpretation.

How can DCLRE1C antibodies be used to characterize primary immunodeficiency disorders?

DCLRE1C antibodies provide valuable research tools for characterizing primary immunodeficiency disorders, particularly those associated with DCLRE1C mutations:

• Diagnostic applications: While not clinical diagnostics themselves, research-grade DCLRE1C antibodies can help characterize protein expression patterns in patient-derived samples, complementing genetic testing. Western blotting and flow cytometry can determine if mutations result in absent protein or expression of truncated variants .

• Genotype-phenotype correlation studies: Antibody-based detection of DCLRE1C can help researchers correlate protein expression levels with disease severity. Studies have shown that compound heterozygosity for one loss-of-function and one hypomorphic allele often results in "leaky SCID" phenotypes with residual protein function .

• Functional characterization: Combining antibody detection with functional assays (such as V(D)J recombination reporter assays or DNA repair measurements) can reveal whether detected DCLRE1C protein retains activity. Research has shown that deletions disrupting the C-terminus often result in truncated but partially functional proteins .

• Therapeutic monitoring: In experimental gene therapy or other interventions aimed at restoring DCLRE1C function, antibodies can help monitor protein expression and localization to assess therapeutic efficacy.

These research applications have advanced our understanding of how different DCLRE1C mutations impact immune function and DNA repair capacity, providing insights that may ultimately improve clinical management of affected patients.

What considerations are important when using DCLRE1C antibodies in cancer research models?

When applying DCLRE1C antibodies in cancer research models, several important considerations should guide experimental design and interpretation:

• Expression variability: Cancer cells often show altered DNA repair pathways, potentially including dysregulated DCLRE1C expression. Researchers should establish baseline expression patterns in relevant normal tissues for comparison.

• Mutation analysis correlation: DCLRE1C antibody staining should be correlated with mutation or expression analysis, as cancer cells may harbor alterations affecting antibody reactivity without completely eliminating protein expression.

• Therapeutic relevance: Since DCLRE1C functions in DNA repair, its expression levels (detected via antibodies) may correlate with sensitivity to radiation therapy or DNA-damaging chemotherapeutics. Artemis-deficient cells show increased sensitivity to double-strand breaks induced by ionizing radiation or agents like bleomycin .

• Resistance mechanisms: Changes in DCLRE1C expression or localization detected by antibody-based methods may reveal adaptive responses or resistance mechanisms in cancer cells exposed to DNA-damaging therapies.

• Technical validation in cancer models: Researchers should validate antibody specificity in their specific cancer models, as altered protein expression, mutations, or post-translational modifications in cancer cells may affect epitope recognition.

Through careful application of these considerations, DCLRE1C antibodies can provide valuable insights into DNA repair dynamics in cancer and potentially identify biomarkers relevant to treatment response.

How are DCLRE1C antibodies being used to explore novel functions beyond V(D)J recombination?

While DCLRE1C is well-established in V(D)J recombination, researchers are using antibodies to explore additional functions:

• General DNA repair mechanisms: DCLRE1C antibodies are being used to investigate Artemis's broader role in non-homologous end-joining (NHEJ) repair of DNA double-strand breaks beyond the context of V(D)J recombination. Artemis-deficient cells show increased sensitivity to ionizing radiation and chemical agents that induce double-strand breaks .

• Cell cycle regulation: Antibody-based detection of DCLRE1C in synchronized cell populations is revealing potential cell-cycle-dependent expression or activity patterns.

• Interaction with novel partners: Co-immunoprecipitation using DCLRE1C antibodies allows identification of previously unknown interaction partners, potentially revealing functions beyond established pathways.

• Post-translational regulation: Phospho-specific antibodies targeting sites like Ser516 are helping elucidate how DCLRE1C activity is regulated through post-translational modifications in response to various cellular stresses .

• Tissue-specific functions: Immunohistochemical analyses with DCLRE1C antibodies across diverse tissue types may reveal unexpected expression patterns suggesting novel functions in non-lymphoid tissues.

These explorations are expanding our understanding of DCLRE1C's role in maintaining genomic integrity across different cellular contexts and physiological conditions.

What methodological advances are improving DCLRE1C antibody applications in research?

Several methodological advances are enhancing the utility of DCLRE1C antibodies in research:

• Super-resolution microscopy techniques: These technologies allow visualization of DCLRE1C localization with unprecedented spatial resolution, revealing detailed subnuclear distribution patterns particularly at DNA damage sites.

• Proximity labeling approaches: Techniques like BioID or APEX, when combined with DCLRE1C antibodies for validation, enable identification of proteins in close proximity to DCLRE1C in living cells, providing insights into its local interaction environment.

• Single-cell analysis integration: Combining antibody-based detection of DCLRE1C with single-cell transcriptomics or proteomics allows correlation of protein expression with broader cellular states.

• CRISPR-engineered reporter systems: Creation of endogenously tagged DCLRE1C alleles provides validation standards for antibody specificity while enabling live-cell tracking of the native protein.

• Quantitative assay systems: As described in the literature, engineered cellular systems with quantifiable readouts (like GFP expression in recombination assays) allow precise measurement of DCLRE1C activity levels when paired with antibody-based detection of protein expression .

These advanced methodologies are pushing the boundaries of what can be learned about DCLRE1C function, particularly in contexts where traditional approaches have been limited by sensitivity or specificity constraints.